Due to network maintenance at the University of Basel, the SWISS-MODEL website will be interrupted this weekend between 07:00 CET Saturday 17th May and 23:55 CET Sunday 18th May.
SMTL ID : 4jyw.1
X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with CTT1057
Coordinates
PDB Format
Method
X-RAY DIFFRACTION
1.73 Å
Oligo State
homo-dimer
Ligands
4 x
NAG-
NAG:
2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG-NAG.1:
5
residues within 4Å:
Chain A:
N.35,
Q.38,
Q.54,
S.57,
Q.58
2 PLIP interactions:
2 interactions with chain A
Hydrophobic interactions:
A:Q.54
Hydrogen bonds:
A:S.57
NAG-NAG.2:
4
residues within 4Å:
Chain A:
N.80,
T.82,
H.83,
T.308
No protein-ligand interaction detected (PLIP)
NAG-NAG.13:
5
residues within 4Å:
Chain B:
N.35,
Q.38,
Q.54,
S.57,
Q.58
2 PLIP interactions:
2 interactions with chain B
Hydrophobic interactions:
B:Q.54
Hydrogen bonds:
B:S.57
NAG-NAG.14:
4
residues within 4Å:
Chain B:
N.80,
T.82,
H.83,
T.308
No protein-ligand interaction detected (PLIP)
2 x
NAG-
NAG-
FUC:
2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-FUC.3:
6
residues within 4Å:
Chain A:
P.84,
Y.86,
E.96,
I.97,
N.99,
L.102
2 PLIP interactions:
2 interactions with chain A
Hydrophobic interactions:
A:P.84,
A:L.102
NAG-NAG-FUC.15:
6
residues within 4Å:
Chain B:
P.84,
Y.86,
E.96,
I.97,
N.99,
L.102
2 PLIP interactions:
2 interactions with chain B
Hydrophobic interactions:
B:P.84,
B:L.102
2 x
NAG-
NAG-
BMA:
beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA.4:
5
residues within 4Å:
Chain A:
S.431,
L.432,
N.435,
P.553,
Q.610
2 PLIP interactions:
2 interactions with chain A
Water bridges:
A:Q.610,
A:Q.610
NAG-NAG-BMA.16:
5
residues within 4Å:
Chain B:
S.431,
L.432,
N.435,
P.553,
Q.610
2 PLIP interactions:
2 interactions with chain B
Water bridges:
B:Q.610,
B:Q.610
2 x
NAG-
NAG-
BMA-
MAN-
MAN:
alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
4 x
NAG:
2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.10:
2
residues within 4Å:
Chain A:
N.154,
S.156
2 PLIP interactions:
2 interactions with chain A
Hydrogen bonds:
A:N.154,
A:S.156
NAG.11:
4
residues within 4Å:
Chain A:
W.205,
N.418,
F.524,
Y.525
5 PLIP interactions:
5 interactions with chain A
Hydrophobic interactions:
A:W.205,
A:Y.525
Hydrogen bonds:
A:W.205,
A:F.524
Water bridges:
A:N.418
NAG.22:
2
residues within 4Å:
Chain B:
N.154,
S.156
2 PLIP interactions:
2 interactions with chain B
Hydrogen bonds:
B:N.154,
B:S.156
NAG.23:
4
residues within 4Å:
Chain B:
W.205,
N.418,
F.524,
Y.525
5 PLIP interactions:
5 interactions with chain B
Hydrophobic interactions:
B:W.205,
B:Y.525
Hydrogen bonds:
B:W.205,
B:F.524
Water bridges:
B:N.418
2 x
T57:
N-{6-[(4-fluorobenzoyl)amino]hexanoyl}-L-gamma-glutamyl-5-{[(S)-{[(1S)-1,3-dicarboxypropyl]amino}(hydroxy)phosphoryl]oxy}-L-norvaline(Non-covalent)
Ganguly, T. et al., A high affinity 18F-labeled phosphoramidate peptidomimetic inhibitor as a PSMA-targeted PET imaging agent for prostate cancer. To be Published
